Effect of ARNI (Sacubitril/Valsartan) and SGLT2 Inhibitors (Dapagliflozin) either alone or in Combination on Heart Failure: An Exploration of Novelty
Authors:
- Girish B. SGSGirish B. S
- Joel M. JohnsJJJoel M. Johns
- C. S MeghanaCMC. S Meghana
- R. SrinivasanRSR. Srinivasan
Open Access
- 23 August 2024
- journal article
- review article
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 16 (3) , 439-446
Abstract
B. S Girish, Joel M. Johns, C. S Meghana and R. Srinivasan Author informationArticle notesCopyright and License informationCitations Corresponding author. Correspondence: Mr. Girish B S Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences (Formerly PES College of Pharmacy), PES University, Electronic City Campus, Bangalore-560100, Karnataka, INDIA. Email: girishsharma70268@gmail.com Received February 17, 2024; Revised March 30,Keywords
This publication has 38 references indexed in Scilit:
- Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanEuropean Journal of Heart Failure, 2022
- Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJACC, 2022
- Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVERNature Medicine, 2022
- Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fractionScientific Reports, 2021
- Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the USJAMA Cardiology, 2021
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trialsThe Lancet, 2020
- Short-term effects of a 3-week interval training program on heart rate variability in chronic heart failure. A randomised controlled trialAnnals of Physical and Rehabilitation Medicine, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort studyActa Diabetologica, 2014
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialThe Lancet, 2012